GH Research (GHRS) Director Moore Duncan Receives 2,202-Share Option Award

What Happened

Moore Duncan, a director of GH Research PLC, was granted 2,202 derivative securities on August 11, 2026. The reported acquisition price is $0.00 (total reported value $0). This is an award/grant of share options (a compensation/award event), not an open-market purchase or sale.

Key Details

• Transaction date: August 11, 2026; Form 4 filed August 13, 2026 (appears timely, within the two-business-day reporting window).
• Transaction type/code: A (Award/Grant/Other Acquisition). Reported price: $0.00; reported total = $0.
• Shares/options granted: 2,202 derivative securities.
• Shares owned after transaction: Not specified in the provided filing data.
• Footnote: The granted share options are immediately fully vested but are not exercisable until August 11, 2028.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag was noted in the summary provided.

Context

This was an options/award grant as part of company compensation. The immediate vesting means the award is not subject to further service-based vesting, but the holder cannot exercise the options until the stated exercisability date (Aug 11, 2028). Such grants are common for directors and reflect compensation rather than an independent cash-market purchase or sale; they do not, by themselves, indicate the insider’s intent to buy or sell stock.